Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 Adipocytokine signaling pathway 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
2 Adipocytokine signaling pathway 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
3 Adipocytokine signaling pathway 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
4 Adipocytokine signaling pathway 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
5 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
7 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
9 Chemical carcinogenesis - receptor activation 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
10 Chemical carcinogenesis - receptor activation 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
11 Chemical carcinogenesis - receptor activation 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
12 Chemical carcinogenesis - receptor activation 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
13 Chemokine signaling pathway 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
14 Chemokine signaling pathway 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
15 Chemokine signaling pathway 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
16 Chemokine signaling pathway 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
17 Cholinergic synapse 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
18 Cholinergic synapse 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
19 Cholinergic synapse 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
20 Cholinergic synapse 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
21 EGFR tyrosine kinase inhibitor resistance 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
22 EGFR tyrosine kinase inhibitor resistance 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
23 EGFR tyrosine kinase inhibitor resistance 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
24 EGFR tyrosine kinase inhibitor resistance 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
25 Growth hormone synthesis, secretion and action 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
26 Growth hormone synthesis, secretion and action 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
27 Growth hormone synthesis, secretion and action 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
28 Growth hormone synthesis, secretion and action 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
29 Hepatitis B 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
30 Hepatitis B 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
31 Hepatitis B 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
32 Hepatitis B 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
33 Herpes simplex virus 1 infection 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
34 Herpes simplex virus 1 infection 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
35 Herpes simplex virus 1 infection 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
36 Herpes simplex virus 1 infection 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
37 Influenza A 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
38 Influenza A 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
39 Influenza A 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
40 Influenza A 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
41 JAK-STAT signaling pathway 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
42 JAK-STAT signaling pathway 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
43 JAK-STAT signaling pathway 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
44 JAK-STAT signaling pathway 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
45 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
46 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
47 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
48 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
49 Leishmaniasis 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
50 Leishmaniasis 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
51 Leishmaniasis 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
52 Leishmaniasis 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
53 Lipid and atherosclerosis 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
54 Lipid and atherosclerosis 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
55 Lipid and atherosclerosis 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
56 Lipid and atherosclerosis 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
57 Necroptosis 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
58 Necroptosis 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
59 Necroptosis 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
60 Necroptosis 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
61 Pathways in cancer 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
62 Pathways in cancer 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
63 Pathways in cancer 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
64 Pathways in cancer 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
65 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
66 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
67 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
68 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
69 PI3K-Akt signaling pathway 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
70 PI3K-Akt signaling pathway 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
71 PI3K-Akt signaling pathway 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
72 PI3K-Akt signaling pathway 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
73 Prolactin signaling pathway 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
74 Prolactin signaling pathway 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
75 Prolactin signaling pathway 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
76 Prolactin signaling pathway 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
77 Signaling pathways regulating pluripotency of stem cells 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
78 Signaling pathways regulating pluripotency of stem cells 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
79 Signaling pathways regulating pluripotency of stem cells 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
80 Signaling pathways regulating pluripotency of stem cells 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
81 Th1 and Th2 cell differentiation 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
82 Th1 and Th2 cell differentiation 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
83 Th1 and Th2 cell differentiation 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
84 Th1 and Th2 cell differentiation 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
85 Th17 cell differentiation 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
86 Th17 cell differentiation 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
87 Th17 cell differentiation 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
88 Th17 cell differentiation 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
89 Toxoplasmosis 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
90 Toxoplasmosis 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
91 Toxoplasmosis 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
92 Toxoplasmosis 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬
93 Tuberculosis 💬
 [1] JAK2 💬 Baricitinib 💬 Baricitinib [13]  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
94 Tuberculosis 💬
 [1] JAK2 💬 Peficitinib 💬 Peficitinib [1] 46 💬
95 Tuberculosis 💬
 [1] JAK2 💬 Ruxolitinib 💬 Ruxolitinib [3] 60, 65, 228 💬
96 Tuberculosis 💬
 [1] JAK2 💬 Tofacitinib 💬 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬

Back to top